top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cingulate Inc. - Warrants (NQ:CINGW)

0.0800 -0.0100 (-11.11%)
Streaming Delayed Price Updated: 2:52 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cingulate Inc. - Warrants

News headline image
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
Data Accepted as Finalist for First Annual Poster Awards 
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
Results Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and Duration 
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
Announcement Confirms Cingulate on Track with Development and Regulatory Milestones 
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate to Present at 13th Annual LD Micro Invitational
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate, Indegene to Participate in Benzinga All Live Access Event
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
Scalable Supply of CTx-1301 Ready to be Produced with Cingulate on Track to Meet Previously Announced Clinical Timelines for Phase 3 Trial Program 
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate to Participate in Benzinga All Live Access Event
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
From Cingulate Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page